Rhumbline Advisers Esperion Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 246,914 shares of ESPR stock, worth $392,593. This represents 0.0% of its overall portfolio holdings.

Number of Shares

246,914

Previous 243,090 1.57%

Holding current value

$392,593

Previous $401,000 35.41%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Jan 30, 2025	BUY	$1.61 - $3.83 $6,156 - $14,645	3,824 Added 1.57%	246,914 $543,000
Q3 2024 Nov 12, 2024	SELL	$1.61 - $2.73 $14,406 - $24,428	-8,948 Reduced 3.55%	243,090 $401,000
Q2 2024 Aug 01, 2024	BUY	$1.84 - $3.24 $456,787 - $804,342	248,254 Added 6560.62%	252,038 $559,000
Q3 2023 Nov 09, 2023	SELL	$0.96 - $1.79 $3,218 - $6,001	-3,353 Reduced 46.98%	3,784 $3,000
Q2 2023 Aug 08, 2023	SELL	$1.2 - $1.76 $111,016 - $162,824	-92,514 Reduced 92.84%	7,137 $9,000
Q1 2023 May 11, 2023	BUY	$1.46 - $7.3 $9,961 - $49,807	6,823 Added 7.35%	99,651 $158,000
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $36,729 - $61,336	7,216 Added 8.43%	92,828 $578,000
Q3 2022 Nov 10, 2022	BUY	$5.45 - $8.13 $53,949 - $80,478	9,899 Added 13.07%	85,612 $574,000
Q2 2022 Aug 11, 2022	BUY	$4.77 - $6.67 $104,920 - $146,713	21,996 Added 40.95%	75,713 $482,000
Q1 2022 May 12, 2022	BUY	$3.34 - $5.56 $75,430 - $125,567	22,584 Added 72.54%	53,717 $249,000
Q4 2021 Feb 10, 2022	SELL	$4.81 - $11.92 $2,303 - $5,709	-479 Reduced 1.52%	31,133 $156,000
Q3 2021 Nov 12, 2021	SELL	$11.34 - $21.37 $14,356 - $27,054	-1,266 Reduced 3.85%	31,612 $381,000
Q2 2021 Aug 05, 2021	BUY	$19.4 - $28.71 $15,655 - $23,168	807 Added 2.52%	32,878 $695,000
Q1 2021 May 06, 2021	SELL	$25.12 - $36.89 $72,245 - $106,095	-2,876 Reduced 8.23%	32,071 $900,000
Q4 2020 Feb 10, 2021	BUY	$24.2 - $35.76 $22,941 - $33,900	948 Added 2.79%	34,947 $909,000
Q3 2020 Nov 12, 2020	SELL	$31.18 - $52.71 $299,639 - $506,543	-9,610 Reduced 22.04%	33,999 $1.26 Million
Q2 2020 Aug 13, 2020	BUY	$30.04 - $51.31 $164,078 - $280,255	5,462 Added 14.32%	43,609 $2.24 Million
Q1 2020 May 06, 2020	SELL	$27.44 - $73.84 $22,061 - $59,367	-804 Reduced 2.06%	38,147 $1.2 Million
Q4 2019 Feb 05, 2020	BUY	$35.4 - $59.82 $100,323 - $169,529	2,834 Added 7.85%	38,951 $2.32 Million
Q3 2019 Oct 23, 2019	BUY	$34.47 - $47.53 $7,238 - $9,981	210 Added 0.58%	36,117 $1.32 Million
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $187,668 - $244,904	4,680 Added 14.99%	35,907 $1.67 Million
Q1 2019 May 01, 2019	SELL	$40.11 - $53.57 $14,279 - $19,070	-356 Reduced 1.13%	31,227 $1.25 Million
Q4 2018 Jan 31, 2019	BUY	$36.99 - $59.11 $363,833 - $581,405	9,836 Added 45.23%	31,583 $1.45 Million
Q3 2018 Nov 07, 2018	SELL	$40.74 - $51.41 $53,532 - $67,552	-1,314 Reduced 5.7%	21,747 $965,000
Q2 2018 Aug 06, 2018	BUY	$36.2 - $76.4 $212,385 - $448,238	5,867 Added 34.12%	23,061 $904,000
Q1 2018 May 02, 2018	SELL	$65.94 - $80.76 $48,795 - $59,762	-740 Reduced 4.13%	17,194 $1.24 Million
Q4 2017 Feb 09, 2018	SELL	$43.47 - $67.43 $111,544 - $173,025	-2,566 Reduced 12.52%	17,934 $1.18 Million
Q3 2017 Nov 06, 2017	BUY	$43.8 - $52.77 $897,899 - $1.08 Million	20,500	20,500 $1.03 Million

Others Institutions Holding ESPR

# of Institutions

215

Shares Held

129M

Call Options Held

1.78M

Put Options Held

1.27M

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $106M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Esperion Therapeutics, Inc. Transaction History